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The COVID-19 pandemic has become a priority in the health systems of all nations
worldwide. In fact, there are currently no specific drugs or preventive treatments such
as vaccines. The numerous therapies available today aim to counteract the symptoms
caused by the viral infection that in some subjects can evolve causing acute respiratory
distress syndromes (ARDS) with consequent admission to intensive care unit. The
exacerbated response of the immune system, through cytokine storm, causes extensive
damage to the lung tissue, with the formation of edema, fibrotic tissues and susceptibility
to opportunistic infections. The inflammatory picture is also aggravated by disseminated
intravascular coagulation which worsens the damage not only to the respiratory system,
but also to other organs. In this context, perinatal cells represent a valid strategy thanks to
their strong immunomodulatory potential, their safety profile, the ability to reduce fibrosis
and stimulate reparative processes. Furthermore, perinatal cells exert antibacterial and
antiviral actions. This review therefore provides an overview of the characteristics of
perinatal cells with a particular focus on the beneficial effects that they could have in
patients with COVID-19, and more specifically for their potential use in the treatment of
ARDS and sepsis.
Keywords: coronavirus-induced disease 2019, severe acute respiratory distress syndrome coronavirus-2,
mesenchymal stromal cells, PLacental eXpanded, perinatal
SARS-CoV2 PATHOLOGY AND THE RATIONALE FOR THE USE
OF MSCs IN THE TREATMENT OF COVID-19 PATIENTS
The Severe Acute Respiratory SyndromeCoronaVirus 2 (SARS-CoV-2) pandemic began inWuhan,
China, in December 2019, and rapidly spread worldwide. The disease caused by SARS-CoV-2 is
called coronavirus disease 2019 (COVID-19) and by December 2020, the disease has reached more
than 61 million cases, with over 1.4 million deaths and the numbers are constantly rising (https://
COVID-19.who.int/).
Patients affected by COVID-19 infection report symptoms such as headache, fever, weakness,
cough, general malaise, and shortness of breath (Chen et al., 2020). Although in many cases the
disease does not lead to the development of symptoms, in around 5% of patients, especially the
elderly, in the presence of co-morbidities like hypertension and diabetes, the disease can become
critical, giving rise to acute respiratory distress syndrome (ARDS), pneumonia and multiple organ
dysfunction requiring intensive care unit treatment (ICU) (Chen et al., 2020; Li et al., 2020). The
mortality rate ranges between 1 and 4% (Guan et al., 2020; Rothan and Byrareddy, 2020), with the
highest percentage in the aged and most critical patients >80 years old (Chen et al., 2020).
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Many of the observed symptoms in ICU patients are
attributable to a widespread and uncontrolled inflammatory
response that gives rise to cytokine storm, as well as a
disseminated intravascular coagulopathy (DIC) and multiorgan
failure (Li et al., 2020).
As a matter of fact, screenings conducted on ICU patients
showed that severe COVID-19 patients had high serum levels
of inflammatory cytokines, such as tumor necrosis factor-alpha
(TNF-α), interleukin-1 beta (IL-1β), IL-6, IL-17, interferon-
gamma (IFNγ), granulocyte colony-stimulating factors (GM-
CSF) and chemokine like the macrophage inflammatory proteins
1-α (MIP-1 α) (De Biasi et al., 2020; Huang et al., 2020; Liu J. et al.,
2020).
Moreover, many patients also tend to develop a symptomatic
framework that meets the diagnostic criteria for sepsis and septic
shock according to the Sepsis-3 International Consensus (Singer
et al., 2016). Importantly, following the inflammatory phase due
to the dysregulated immune response, many patients develop
lymphopenia, and thus are subject to other infections due to
lowered immune response (Tan et al., 2020).
At the moment there is no specific treatment for SARS-
CoV-2 infection and its consequences. Several clinical trials have
been conducted using drugs targeting cytokines responsible for
the observed adverse effects such as tocilizumab that targets
IL-6 (Guaraldi et al., 2020; Stone et al., 2020), or anakinra
to counteract the effects related to IL-1β (NCT04443881,
NCT04603742, Huet et al., 2020). Other antiviral drugs such
as Remdesivir are still present in therapeutic protocols today,
finding an application in limiting viral replication (Beigel et al.,
2020).
Mesenchymal stromal cells (MSCs) represent a possible
alternative treatment for COVID-19 aimed at counteracting the
damage and organ failure due to inflammatory and fibrotic
processes induced by SARS-CoV2, as well as responding to many
of the symptoms induced by the viral infection. In fact, MSCs
have been studied for years in regenerative medicine for the
immunomodulatory properties that make them suitable for the
treatment of many chronic or degenerative diseases, where the
immune response is dysregulated (Shi et al., 2018; Koliaraki
et al., 2020). Furthermore, these cells are also characterized by
antimicrobial properties (Alcayaga-Miranda et al., 2017) and
reduced expression of HLA-II strongly reducing the risk of
allograft rejection (Ryan et al., 2005).
Initially isolated from the bone marrow over the years they
have been isolated from different tissues such as adipose tissue,
dental pulp, and perinatal tissues (Silini et al., 2020). In particular,
in this review we will focus our attention on the potential
application of perinatal derived cells (PDCs) in the treatment
of COVID-19 with a focus on their anti-inflammatory and
antifibrotic properties, aimed at counteracting ARDS, and on
their antimicrobic and antiviral properties.
PERINATAL TISSUES AS A PRECIOUS
CELL SOURCE
The use of cell therapy has attracted much attention in
the scenario of regenerative medicine due to its potential
therapeutic benefits. Indeed, living cells provide multifaceted
mechanisms of action that can tackle a broad spectrum of
deregulated physiological processes especially in degenerative
and inflammatory diseases.
One of the most intriguing sources for cell therapy that
has attracted much attention in the past decade is perinatal
tissues. The term “perinatal” refers to birth-associated tissues
that are obtained from term placentas (including chorionic
villi, chorionic plate) and fetal annexes (that include amniotic
and chorionic membrane, amniotic fluid, and umbilical cord).
Indeed, perinatal tissues have proven to be precious reservoirs of
cells (In ’t Anker et al., 2004; Wang et al., 2004; De Coppi et al.,
2007; Parolini et al., 2008; Abumaree et al., 2013).
Initially, perinatal tissues drew attention as an interesting cell
source due to their early embryological origin suggesting that
perinatal cells could possess unique plasticity and differentiation
properties (Parolini and Soncini, 2006). In addition, when
compared to other cell sources such as bone marrow, practical
and logistical reasons made the placenta an attractive cell source.
It is easily obtained after birth without invasive procedures, and
it is considered biological waste thus bypassing ethical tensions
associated to other cell sources.
Nowadays, perinatal-derived cells (PDCs) have obtained
significant recognition for their promising applications in
regenerative medicine (Silini et al., 2015). As a matter of
fact, during this past decade the literature published on PDCs
has grown exponentially, substantiating the interest in using
cells from these tissues and, most importantly, demonstrating
that indeed PDCs are important contenders with stromal cells
from other tissues, such as bone marrow- or adipose-derived
mesenchymal stromal cells (MSCs). Below we will briefly discuss
why perinatal cells represent valid alternatives.
First, there is strong evidence that PDCs from both maternal
and fetal tissues do not induce an immune response in vitro
(Bailo et al., 2004; Wolbank et al., 2007; Banas et al., 2008;
Magatti et al., 2008; Weiss et al., 2008; Prasanna et al., 2010;
Tipnis et al., 2010; Papait et al., 2020), making them attractive
for allogeneic transplantation. Second, in order to become fully
immunosuppressive, several studies indicate that MSCs from
bone marrow require “licensing” with inflammatory stimuli
such as IFNγ and TNFα (Krampera et al., 2006; Ren et al.,
2008; Sheng et al., 2008; Mougiakakos et al., 2011; Shi et al.,
2012). Accordingly, bone marrow MSCs cultured in transwell,
and the secretome from bone marrow MSCs, are not able to
exert suppressive effects if they are not previously exposed to
inflammatory stimuli (Krampera et al., 2003, 2006; Groh et al.,
2005). In the case of PDCs, “licensing” does not seem to be
mandatory for their suppressive effects (Magatti et al., 2008; Rossi
et al., 2012; Lange-Consiglio et al., 2020; Papait et al., 2020)
although stimulation of PDCs with pro-inflammatory cytokines
has been shown to increase secretome potency (Allen et al.,
2018). In line with this, the secretome from unstimulated PDCs
exerts significant immunomodulatory effects in vitro (Rossi et al.,
2012; Pianta et al., 2015; Magatti et al., 2016; Papait et al., 2020)
and therapeutic effects in vivo in diseases with a deregulated
inflammatory response (Cargnoni et al., 2012, 2014; Roy et al.,
2013; Danieli et al., 2015; Chatterjee et al., 2016; Magatti et al.,
2016; Van Linthout et al., 2017; Giampa et al., 2019), altogether
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suggesting that these cells constitutively secrete bioactive factors
that promote regeneration.
Third, PDCs and their secretome have robust therapeutic
properties when transplanted in animal models of
different pathological conditions, such as inflammatory
disorders, autoimmune diseases, neurodegenerative diseases,
ischemia/reperfusion injuries, diabetes, and liver and lung
fibrosis. The controversial ability of PDCs to differentiate
in vivo, as well as the low survival and engraftment in
host tissues after transplantation, suggest that they do not
act via stemness properties to replace injured tissue but
rather act via paracrine mechanisms on tissue resident cells
or on immune cells located in the injured tissue. PDCs
can create a reparative environment through cell-to-cell
contact and the secretion of growth factors, cytokines, and the
release of extracellular vesicles (containing peptides/proteins,
mRNA, and microRNA). These in turn can suppress the
activation/function of inflammatory cells; prevent apoptosis
and promote the survival of damaged tissue cells, reduce
oxidative injury often involved in tissue damage, and
favor angiogenesis.
The immunomodulatory activity of PDCs includes inhibition
of immune cell (e.g., T and B lymphocyte) proliferation (Magatti
et al., 2008, 2020; Weiss et al., 2008; Najar et al., 2010a;
Prasanna et al., 2010; Raicevic et al., 2011; Zhou et al., 2011;
Roy et al., 2013; Li et al., 2014; Wang et al., 2014; Pianta
et al., 2016; Cargnoni et al., 2020; Papait et al., 2020), inhibition
of the maturation toward effector immune cells (cells which
actively respond to an immunogenic stimuli) (Magatti et al.,
2009; Pianta et al., 2016), expansion of regulatory immune cells
that can suppress the immune response (Chang et al., 2006;
Najar et al., 2010b; Parolini et al., 2014; Amari et al., 2015;
Pianta et al., 2015, 2016; Papait et al., 2020), inhibition of the
secretion of pro-inflammatory cytokines and chemokines (IL-
1β, IL-2, TNF -α, and IFN-γ) (Kronsteiner et al., 2011; Kang
et al., 2012; Karlsson et al., 2012; Parolini et al., 2014; Pianta
et al., 2015), involved in the aggravation of the inflammatory
response, and promotion of the production of anti-inflammatory
factors (IL-10, TGF-β), (Pianta et al., 2015; Papait et al.,
2020).
The promising findings obtained from preclinical studies,
along with the high availability, excellent safety profile, lack of
ethical challenges, and low immunogenicity, provide a strong
rationale for investigating perinatal cells as a potential innovative
therapy in humans.
PDCs APPLIED IN CLINICAL TRIALS FOR
PULMONARY DISORDERS
Over the past decade a large number of clinical trials have
emerged worldwide using cell-based therapies to treat various
diseases (clinicaltrials.gov), including neurological disorders,
muscle repair, cardiovascular diseases, immune related diseases,
and lung diseases. Among these studies the use of PDCs is rapidly
rising with only 1% of the studies using perinatal tissues as a
source of cells, between the years 1994 and 2009, to almost 30%
in 2018 (Verter et al., 2018; Moll et al., 2019).
According to a large analysis of 914 MSC trials reported
through 2018 (Kabat et al., 2020), the three most common
conditions for MSC trials are neurological, joint, and
cardiovascular diseases which account for 42% of all trials.
Pulmonary conditions account for only about 6% of all trials
(Marquez-Curtis et al., 2015; Kabat et al., 2020). However,
since the emergence of the novel coronavirus disease (COVID-
19), that features pathological changes that are similar to
acute lung injury with serious pulmonary inflammation and
inflammatory cytokine storm, numerous clinical trials with
MSCs as a new treatment for COVID-19 were registered
(Liu S. et al., 2020). Indeed, as of July 2020 there were 83
clinical trials (clinicaltrials.gov) using MSCs for various
immune/inflammatory pulmonary conditions (Figure 1A) and
57% of these (47 out of 83) were specifically for COVID-19.
With respect to the source of the MSCs, perinatal tissues account
for 40% of all pulmonary studies and 49% of the COVID-19
trials (Figure 1B). Results obtained from clinical trials which
transplanted PDCs intravenously (IV) in patients with lung
fibrosis have shown that these cells are safe with null/mild side
effects. Specifically, in a phase 1 clinical trial, PDCs (PDA-001)
infused in four patients with refractory pulmonary sarcoidosis
produced a transient and mild increase in mean pulmonary
artery pressure. In the year following treatment two of the
patients showed improvement in their chest x-ray and had
prednisone withdrawn (Baughman et al., 2015). Another phase
1b study using placental stromal cells to treat eight patients
with mild to moderate idiopathic pulmonary fibrosis (IPF)
demonstrated that 6 months after placental MSC infusion,
lung function and CT fibrosis scores were stable from baseline,
proving feasibility and short-term safety of placental MSCs
(Chambers et al., 2014). Patients tolerated cell administration
with only a transient fall of oxygen saturation but no changes in
hemodynamics showing satisfactory short-term safety profile in
IPF patients (Chambers et al., 2014).
In addition, a case report at the Siping Hospital of China
Medical University described that, at the end of 12 month
follow-up, a 56-year-old patient with IPF that was IV-injected
with human umbilical cord MSCs showed a relevant reduction
of oxygen therapy requirement, an improvement of physical
performance and respiratory parameters (lung function and
CT scores). No serious or clinically relevant side effects were
observed during the entire study period (Zhang et al., 2017).
Finally, a completed phase 1 clinical trial (NCT02277145),
without published results, investigated the effects of clinical
grade umbilical cord MSCs, injected directly into lung lesion
by fiberoptic bronchoscopy in patients with radiation-induced
pulmonary fibrosis. Six months from injection, the safety and
effectiveness of the treatment will be evaluated through CT
density histogram and the patients’ self-evaluation.
Numerous clinical trials are currently evaluating the efficacy
and safety of PDCs applied as treatment for acute respiratory
distress syndrome (ARDS) induced by COVID-19 infection.
Many countries promoted these studies including China, US,
Europe (France, Spain, UK, Ukraine), and South America
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FIGURE 1 | Clinical trials using cell-based therapy for pulmonary disorders. (A) Clinical trials as reported on clinicaltrials.gov (as of July 1, 2020) with stromal cells for
pulmonary conditions. Colors represent the different cells used in the studies. ARDS, acute respiratory distress syndrome; IPF, idiopathic pulmonary fibrosis; ILD,
interstitial lung disease; COPD, chronic obstructive pulmonary disease. (B) Percentage of MSCs from different tissues used in COVID-19 clinical trials.
(Colombia). These studies, registered at www.clinicaltrials.gov,
combine standard of care with the infusion of human umbilical
cord or Wharton’s jelly derived MSCs (hUC-MSCs and hWJ-
MSCs, respectively), or with the intramuscular (IM) injection
of placental expanded adherent stromal cells (NCT04614025,
NCT04389450) to evaluate the ability of cell therapies to
potentiate conventional treatment efficacy for COVID19. Out
of these studies one study will use placenta-derived multipotent
mesenchymal stromal cells (NCT04461925) and another, the
REALIST study, will apply a selected cell population and
specifically CD362 enriched hUC-MSCs to treat patients with
moderate to severe ARDS (NCT03042143).
Most of these studies plan to implementmultiple cell infusions
with cell doses ranging from 1 × 106 cells/kg (NCT04313322,
NCT04429763, NCT03608592, NCT04339660, NCT04457609,
NCT04461925, NCT04390139, NCT04333368), to 5 × 106
cells/kg (NCT04273646) or independent from body weight, doses
ranging from 4 to 5 × 107 cells (NCT04288102, NCT04390152)
and up to 1–6 × 108 cells (NCT04456361, NCT04355728,
NCT04389450). One of these studies is a Phase 1/2a dose-
escalating study (NCT04452097) assessing the safety and the
maximum tolerated dose of IV infused hUC-MSCs. In the phase
1 three doses will be infused 0.5 × 106, 1.0 × 106, or 1.5 ×
106 cells/kg/body weight with three patients/group; at day 3 the
incidence of infusion-related adverse events will be evaluated
and at day 28 the incidence of any treatment-emergent serious
adverse events. In the phase 2a, a total of 30 subjects will be
randomized into the treatment and control groups.
Almost all studies are aimed to assess the efficacy of cell
therapy by evaluating intergroup (cell treated group vs. placebo
group) differences for clinical parameters such as mortality rate,
length of hospitalization, oxygenation index (PaO2/FiO2); one of
these studies (NCT04339660) has the primary endpoint to assess
the improvement of inflammatory parameters/factors such as
plasma levels of TNF-α, IL-1β, IL-6, TGF-β, IL-8 and C-reactive
protein (CRP).
Although most are Phase I or Phase I/II clinical trials,
few of these (NCT04269525, NCT03042143, NCT04288102,
NCT04429763, NCT04389450, NCT04614025) are Phase II trials
that will collect preliminary data on cell therapy efficacy, in
addition to data about safety and short-term adverse events.
In general, however, all these studies will involve a small
numbers of patients, from a few participants (five to nine
patients) to a maximum of 140 (NCT04389450), to have
conclusive indications on PDCs’ safety and efficacy in COVID-
19 patients, cells will be administered in large, randomized,
controlled, double-blinded trials with long-term follow-up.
Considering these important limitations, it cannot be ignored
that some published reports of early phase studies performed
in China show promising results from PDC therapy in severe
cases of COVID-19. In a Phase I study (Meng et al., 2020),
18 patients with moderate-severe COVID-19 were enrolled and
received standard COVID-treatment regimens, nine of them (the
treated group), also received three IV infusions of hUC-MSCs
(1 × 106cells/each infusion) on days 0, 3, and 6. Two patients
from the treated group suffered from transient facial flushing and
fever, and another from transient hypoxia at 12 h post infusion.
A reduced number of patients in treated group with respect
to control group (1 vs. 4), required mechanical ventilation and
experienced dyspnea (1 treated vs. 5 controls). Furthermore,
hUC-MSC-treated patients showed a trend in reduction of serum
IL-6. On the basis of these outcomes, the authors started a
Phase 2 randomized placebo-controlled trial which will recruit
90 patients with severe COVID-19 (see NCT04288102).
From January to April 2020, another clinical study enrolled
31 patients with severe COVID-19, all treated with one to three
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FIGURE 2 | Etiopathology of the Sars-CoV2 viral infection and therapeutic effect of PDCs injection. (A) Sars-CoV2 is responsible for acute respiratory distress
syndrome (ARDS) resulting in thousands of patients requiring intensive care unit (ICU) treatment. Importantly, the virus responsible of trigger an exacerbated immune
response, resulting in a cytokine storm, and consequently to the damage of the epithelial airway, followed by lung edema, dysfunction of air exchange and the
formation of interstitial fibrosis, thus creating an environment conducive to opportunistic bacterial infections or superinfection. Furthermore, COVID-19 is characterized
also by the formation of vascular microthrombi that are often identified in areas of diffuse alveolar damage and are associated with diffuse endothelial damage. (B)
PDCs treatment can directly affect the immune response through the release of immunomodulatory cytokines, such as IL-10, or anti-inflammatory molecules such as
Prostaglandin (PG) E2, thus immunomodulating the exacerbated inflammatory response. Furthermore, MSCs can exert beneficial properties through the release of
anti-microbial peptides such as LL-37. Moreover, PDCs can degrade or inhibit ARDS-induced fibrotic tissue by remodeling the extracellular matrix through the release
of metalloprotease and TIMP, and modulation of the immune response can consequently reduce the formation of microthrombi affecting the alveolar capillaries.
Created with Biorender.com.
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 5 January 2021 | Volume 8 | Article 619980
Papait et al. Perinatal Cells for COVID-19
doses of hUC-MSCs (1 × 106cells/kg each dose) suspended
in 100ml saline (Guo et al., 2020). The authors observed no
adverse events attributable to IV cell infusion. Four patients
died, 27 were discharged with amelioration of clinical and
hematologic parameters, but lack of the control group did not
allow conclusions to be drawn on potential treatment efficacy.
Another study, published by Shu et al. (2020), enrolled
41 patients with severe COVID-19 who did not respond
to a 7- to 10-day standard treatment. All patients received
conventional treatment (ventilation, antiviral agents, antibiotic
agents if needed, glucocorticoid therapy) and, in addition, a
group of these patients (n = 12), received one IV infusion
of hUC-MSCs (2 × 106cells/kg in 100ml saline). During
2 week-period of observation, patients who received hUC-
MSCs, had no adverse reactions. In comparison with control
group (n = 29), treated patients showed a shorter time to
clinical improvement (9.0 vs. 14.0 days, p = 0.006), a higher
percentage with significant remission of dyspnea and absorption
of imaging (91.67 vs. 51.72%), a better oxygenation index, and
a significant amelioration of CT scores, ground-glass opacity
and consolidation, paralleled with reduced plasmatic levels of
CRP and IL-6; all are parameters that indicate reduced lung
inflammation. The authors speculate that hUC-MSCs can reduce
lung inflammation by reducing the release of inflammatory
cytokines through an immunomodulatory action.
In most of the completed and ongoing studies, COVID-
19 patients received/will receive PDCs through IV infusion,
however it is not yet clear whether the IV route is the best choice.
COVID-19 can lead to a form of disseminated intravascular
coagulation (DIC) and many of the critically ill COVID-19
patients with poor prognosis are in a systemic procoagulant state
(Arachchillage and Laffan, 2020; Connors and Levy, 2020; Klok
et al., 2020; Magro et al., 2020; Oxley et al., 2020; Spyropoulos
et al., 2020; Tang et al., 2020; Wang T. et al., 2020; Zhang
et al., 2020; Zhou et al., 2020), and MSC products are known
to express variable levels of a highly procoagulant tissue factor
(TF/CD142) (Morrissey, 2004). Therefore, alternative routes of
cell administration such as the IM injection are increasingly
explored. The IM route holds great advantages over other
administration routes, such as the possibility to administer a
higher number of cells and thus potentially increase efficacy
(Braid et al., 2018; Caplan et al., 2019), and the vascularized
muscle support provides a channel for systemic release of
paracrine mediators. In addition, the large muscle tissue allows
for multiple injection sites (Caplan et al., 2019; Hamidian
Jahromi and Davies, 2019). IM delivery has been shown to be
safe (reviewed in Caplan et al., 2019; Hamidian Jahromi and
Davies, 2019) in several clinical studies (Winkler et al., 2018;
Norgren et al., 2019) with placenta-derived mesenchymal-like
cells [PLacental eXpanded (PLX)-PAD] and is now being tested
in a double-blind, multicenter study to evaluate the efficacy of
PLX-PAD for the treatment of COVID-19 (NCT04389450). PLX-
PAD cells are adherent stromal cells isolated from the placenta
of healthy women following a cesarean section. While PLX-
PAD cells express membrane markers typical of classical MSCs,
they have a minimal ability to differentiate in vitro into cells
of the mesodermal lineage and are thus termed MSC-like cells.
In addition to the previously mentioned phase II study, PLX-
PAD are also being used (as of July 2020) to treat 20 COVID-19
patients in Israel under emergency/compassionate use, and in the
USA under Single Patient IND for Compassionate or Emergency
Use. Patients received either one or two treatments of 300 million
cells administered via IM injections. Data published on the first
eight patients describe an overall good safety profile and clinical
improvement in several parameters such as CRP, PEEP, and P/F
following PLX-PAD treatment. Specifically, levels of CRP in all
patients were elevated prior to PLX-PAD treatment with levels
ranged from 82 to 394mg/L at time of treatment. Starting as early
as 24 h post treatment, CRP levels decreased and have decreased
by 45 and 77% by day 3 and by day 5, respectively (Barkama et al.,
2020).
PDCs IN LUNG FIBROSIS
Pulmonary Fibrosis and SARS-CoV-2
Infection
Recent evidence has suggested a link between lung fibrosis and
the SARS-CoV-2 virus infection. Indeed, COVID-19 patients
experience a large spectrum of pulmonary fibrotic diseases from
fibrosis associated with pneumonia to major, widespread fibrotic
changes of the lung (George et al., 2020). A longitudinal study
conducted by Wang Y. et al. (2020) on computed tomography
(CT) manifestations during the course of COVID-19 pneumonia
reported that, in the early stage of disease (first 11 days),
∼85% of enrolled patients showed pulmonary ground-glass
opacity and tissue consolidation. Later, between days 12 and 17,
evolving from ground-glass opacity, a mixed pattern with lung
architectural distortion appeared, characterized by perilobular
abnormalities, suggesting the presence of secondary organizing
pneumonia. Given that organizing pneumonia possibly evolves
to fibrosis with progressive and permanent lung damage, this
may indicate that some patients, although negative for COVID-
19 at their discharge, can develop progressive, fibrotic irreversible
interstitial lung disease (Figure 2A) (George et al., 2020;Wang Y.
et al., 2020).
Furthermore, early analysis from patients with COVID-
19 at hospital discharge suggests a high rate of lung fibrotic
abnormalities (George et al., 2020). However, the relation
between the presence of fibrotic lesions and prognosis is under
debate. Some researchers indeed suggest that the presence of
fibrosis indicates a resolution status of the disease and a good
prognosis (Pan et al., 2020). Others instead suggest that fibrosis
may progress resulting in pulmonary interstitial fibrosis disease
indicating a poor prognosis (Kong and Agarwal, 2020). Similar
fibrotic lesions were previously observed in patients surviving
from respiratory diseases caused by coronaviruses (SARS-CoV
and MERS-CoV) similar to the SARS-CoV-2 virus responsible
of COVID-19. Long-term studies indicated that a third of SARS
patients who recovered from severe infection were left with
permanent lung damage (Cox, 2020).
Similarly, long-term studies will be required to establish
the real prevalence of post-COVID-19 fibrosis. However,
due to pandemic nature of COVID-19, some researchers
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underline the prompt need to identify early biomarkers in
the disease course to identify patients who potentially progress
to pulmonary fibrosis (George et al., 2020; Spagnolo et al.,
2020), and suggest that the delivery of antifibrotic therapy,
combined with anti-inflammatory treatment to mitigate the
cytokine storm that seems to be responsible of severe ARDS
thought to trigger the development of lung fibrosis, might
have a role in preventing fibrosis progression after SARS-CoV-
2 infection.
The development of anti-fibrotic drugs able to restore
lung function in IPF patients remains an open challenge.
Current antifibrotic therapy applied to patients with
IPF, mainly represented by nintedanib and pirfenidone,
can slow the progression of the disease and improve
the rate of mortality, however they do not reverse the
fibrotic process, and the only approach to effectively
resolve pulmonary damage remains lung transplantation
(Chase and Gallicchio, 2019). Therefore, there is a need
for new therapeutics with anti-fibrotic effects on the
injured lungs.
PDCs are widely considered as possible treatment for
inflammatory-based fibrotic diseases. These cells, and their
derivatives such as cell-derived exosomes and soluble factors,
possess anti-inflammatory, anti-fibrotic, anti-apoptotic, and
regenerative properties which altogether may synergistically
contribute to stop and reverse fibrotic disease.
PDCs and Derivatives in Animal Models of
Pulmonary Fibrosis
The ability of PDCs and their derivatives to slow and/or
reverse pulmonary fibrosis has been mostly investigated in
mousemodels of bleomycin-induced lung fibrosis that represents
the most used to study pulmonary fibrosis and to test
possible anti-fibrotic drugs (Peng et al., 2013). In this model,
bleomycin induces oxidative stress specifically to alveolar
epithelial cells leading to acute alveolar injury, and a consequent
inflammatory response with immune cell infiltration in lung
parenchyma and secretion of inflammatory and pro-fibrotic
cytokines. Lung inflammation triggers the fibrotic response
characterized by fibroblast activation tomyofibroblasts, cells with
high proliferation and responsible of excessive production of
extracellular matrix that disrupts the normal lung architecture
with loss of respiratory capacity (Peng et al., 2013). Given the
involvement of an inflammatory trigger, it has been hypothesized
that therapeutic approaches with a positive outcome in the
bleomycin model might be beneficial also in COVID-19, both
during the acute inflammatory phase and in preventing long-
term fibrotic complications (George et al., 2020).
PDCs, including those from amniotic membrane, Wharton’s
jelly, and related derivatives, including cell secretome and
secretome-derived exosomes, have been administered in animals
with pulmonary fibrosis to evaluate their ability to prevent
disease (delivery concomitant to fibrosis induction) (Cargnoni
et al., 2009; Moodley et al., 2010; Murphy et al., 2011) and to
evaluate their potential to cure the disease (delivery after fibrosis
establishment) (Moodley et al., 2013; Vosdoganes et al., 2013).
Human Amniotic Epithelial Cells (hAEC)
hAEC and their derivatives are the most studied perinatal cells
in experimental models of lung fibrosis. The antifibrotic effect
of these cells have been investigated when delivered within
24 h from fibrosis induction by bleomycin (Moodley et al.,
2010; Murphy et al., 2011) and when delivered at days 7 or
14 post bleomycin induction when lung injury was established
(Moodley et al., 2013; Vosdoganes et al., 2013; Tan et al., 2018).
However, globally these studies suggest that hAEC can not
only slow down fibrosis progression, but also partly reverse the
established fibrotic lesion. Furthermore, the lower levels of pro-
inflammatory and pro-fibrotic cytokines (MCP-1, TNF-α, IL-1,
IL-6, TGF-β), suggest that hAECmay exert their reparative effects
by modulating the host inflammatory response.
Other studies demonstrate the ability of hAEC to interfere
with specific immune cells involved in the bleomycin-induced
inflammatory response. Murphy et al. (2012) observed that
the therapeutic effect of hAEC depends upon the presence
of functional macrophages and Tan and collaborators (Tan
et al., 2015) demonstrated that hAEC treatment promotes the
switch fromM1 (pro-inflammatory activity), to M2macrophages
(associated with fibrosis resolution) characterized by lipoxin A4-
dependent upregulated phagocytosis (Tan et al., 2017). The same
group showed that hAEC can partly counteract T cell-mediated
inflammation by increasing pulmonary levels of regulatory T
cells (Treg) (Tan et al., 2015). Furthermore, they found that
exosomes from hAEC, when delivered early after bleomycin-
challenge, exerted an anti-inflammatory effect on macrophages
and neutrophils, while a delayed delivery (7 days after bleomycin)
was able to improve tissue-to-airspace ratio and reduce fibrosis
(Tan et al., 2018), indicating that a cell-free treatment derived
from hAEC (i.e., exosomes) can counteract both the pulmonary
inflammatory phase and the following fibrotic phase induced by
bleomycin challenge.
Human Amniotic Mesenchymal Cells (hAMSC)
In a model of pulmonary fibrosis induced by a dual bleomycin
doses to better reflect the repeated injuries that underlie
most lung diseases, Moodley et al. (2013) compared the
antifibrotic potency of hAMSC, hAEC, and BM-MSC. All
reduced infiltration of inflammatory cells in lung parenchyma
and reduced lung levels of the profibrotic cytokine TGF-
β. Interestingly, only hAMSC effectively reduced collagen
deposition. In another study, hAMSC mixed with hAEC and
human chorionic MSCs reduced the severity and extension
of lung fibrosis and decreased neutrophil infiltration when
delivered 15min after bleomycin challenge (Cargnoni et al.,
2009). Interestingly similar effects, together with improved blood
gas parameters, were found when the hAMSC secretome was
used (Cargnoni et al., 2012, 2014), indicating that hAMSC
secrete active mediators crucial for tissue repair. More recently,
hAMSC were found able to reduce collagen deposition, T cell
lung infiltration, and inflammatory cytokine expressions also
in rats with paraquat-induced lung fibrosis (He et al., 2020).
Another recent study reported that administration of human
placental MSC of fetal origin (hfPMSC), isolated from an
unspecified region of placenta, in mice with bleomycin-induced
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lung fibrosis reduced collagen deposition and the production
of pro-fibrotic cytokines by attenuating the dysregulation of
MyD88/TGF-β signaling axis that is considered involved in
the pathogenesis of pulmonary fibrosis in mice (Li et al.,
2017). Finally, a very recent study demonstrates that hAMSC
delivery in bleomycin-challenged mice reduces pulmonary B
cell recruitment, retention and maturation, and counteract
the formation and expansion of intrapulmonary lymphoid
aggregates, thus dampening chronicization of lung inflammatory
processes with a consequent reduction in fibrosis progression
(Cargnoni et al., 2020).
Human Umbilical Cord Mesenchymal Stromal Cells
(hUC-MSC)
Mesenchymal cells derived from the human umbilical cord
(includingWharton’s jelly, herein collectively referred to as hUC-
MSC), have also been extensively investigated in experimental
models of lung fibrosis. The first study performed with these
cells reported that IV injection in immunodeficient mice (SCID)
24 h post-bleomycin challenge decreased lung inflammatory cell
infiltrate and the expression of pro-inflammatory (MIF, TNF-α
and INF-g) and pro-fibrotic cytokines (TGF-β). hUC-MSC also
reduced collagen interstitial levels which could be correlated to
the pro-degradative milieu created by increased MMP-2 levels
and reduced their endogenous inhibitors (Moodley et al., 2009).
Similar findings related to hUC-MSC ability to reduce collagen
deposition were reported in a more recent study where hUC-
MSC were administered twice (24 h and 7 days post-bleomycin)
(Moroncini et al., 2018). In addition, hUC-MSC reduced the
expression of IL-6 and levels of M2 macrophages.
hUC-MSC have been also used in the effort to revert
pulmonary fibrosis induced by bleomycin in lung left lobe
of rats. In this case, cells were administered at day 21
after bleomycin challenge. hUC-MSC transplantation reduced
fibroblast activation and collagen accumulation associated with
preserved alveolar structure and gas exchange (Chu et al.,
2019). Furthermore, in contrast to Moroncini et al. (2018),
hUC-MSC increased levels of pulmonary M2 macrophages
producing matrix metallopeptidase 9 (MMP-9) involved in
collagen degradation. Hyaluronan, released from hUC-MSC,
appeared to be involved in macrophage polarization to an M2-
like phenotype (Chu et al., 2019).
Recently, to improve the migration and homing of
transplanted cells toward injured tissues, CXCR4 over-expressing
hUC-MSC were IV injected in a murine model of radiation-
induced lung injury (Zhang et al., 2019). A higher number of
CXCR4-overexpressing hUC-MSC reached the injured lung
tissues with respect to “normal” hUC-MSC and were more
effective in decreasing the radiation-induced lung injury. Indeed,
a marked reduction in the expression of the pro-fibrotic cytokine
TGF-β1 and of α-SMA and collagen I was reported. Furthermore,
CXCR4-overexpressing hUC-MSC preserved the expression
of E-cadherin, suggesting that cell treatment can inhibit the
radiation induced epithelial-mesenchymal transition (EMT)
process and fibroblast activation into myofibroblasts. The same
study reported that transplanted CXCR4-overexpressing hUC-
MSC could express pro-Surfactant Protein (SP)-C, a marker of
alveolar epithelial II cells, suggesting a possible differentiation
of hUC-MSC into alveolar epithelium when transplanted in
vivo one day after radiation (Zhang et al., 2019). Finally, MSCs
derived from the umbilical cord vein (hUCV-MSC), not from the
stromal tissue of umbilical cord, were transplanted in bleomycin
challenged mice after previous exposure to oxygen peroxide
(H2O2) and, similar to hUC-MSC, preserved alveolar spaces,
reduced TGF-β and α-SMA expressions and myeloperoxidase
activity, indicative of reduced lung inflammation (Mahmoudi
et al., 2020).
MSCs ANTI-MICROBIAL EFFECTS
It is known that MSCs and other stromal cells present
antimicrobial activities, as well as resistance or partial resistance
to viral infection (Li et al., 2016; Khoury et al., 2020). Importantly,
MSCs and other stromal cells including those of perinatal origin
can exert antimicrobial effects either by limiting viruses/bacteria
cell colonization and replication, or by limiting complications
due to a dysregulated host response to infection such as sepsis. At
the moment there are only a few studies reporting the antiviral
and antimicrobial effects of perinatal stromal cells. Indeed, the
most part of the effects herein reported were observed using other
sources of MSCs, such as bone marrow, so we have highlighted
those that resulted from studies conducted with perinatal MSCs.
Thus, in the following sections we will provide an overview of
the applications of MSCs for the treatment of viral infections
and sepsis.
Antiviral Properties of MSCs
Antiviral properties of MSCs have been studied in animal
models of respiratory virus infections with controversial findings
(Khoury et al., 2020). On one hand many studies report
the ability of MSCs to counteract the damage caused by the
virus exerting a protective action, putatively also through their
immunomodulatory activity that is able to counteract an altered
immune response. On the other hand, it should be emphasized
that, other studies report how the susceptibility of MSCs to viral
infection can alter their immunomodulatory properties while
others report limited or negligible results upon MSCs treatment.
Indeed, in an immune-competent mouse model of H9N2
AIV-induced acute lung injury, (Li et al., 2016) reported how a
single IV injection of BM-MSCs 30min after the administration
of the virus significantly improved physiological parameters
with reduction in mortality, lung edema, and histologic injury.
Furthermore, they reported reduced levels of inflammatory
cytokines and chemokines (Li et al., 2016). On the other hand,
systemic administration of BM-MSC in an immune-competent
mouse model of lung injury by H1N1 infection, supplemented
or not with the antiviral oseltamivir, did not improve overall
survival or lung injury (Darwish et al., 2013). These findings
where confirmed by another group that reported how BM-MSCs
injection failed to prevent the damage induced by PR8 infection.
Furthermore, another study conducted on lung MSC isolated
from 1 to 2 week-old specific pathogen free chickens lungs
susceptible to influenza virus infection. The authors showed
that MSCs infected with two avian influenza viruses, H1N1
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and H9N5, became reservoirs and replication sites for the virus
itself. Moreover, the lung MSCs changed their secretome profile
with increased release of inflammatory cytokines such as IL-
6 and IL-8 and became apoptotic (Khatri et al., 2010). Similar
findings were obtained by Cheung et al. (2016) who reported
how the respiratory syncytial virus (RSV) was able to infect
both human BM-MSCs as well as UC-MSCs modifying their
immunomodulatory properties. Indeed RSV-infected MSCs had
increased expression of IL-1β, IL-6, IL-8, and SDF-1, and also
showed an altered capacity to affect PBMC proliferation (Cheung
et al., 2016).
However, other groups have reported that MSCs prevented
influenza-induced thrombocytosis and partially reduced the viral
load (Gotts et al., 2014). The protective effect exerted by theMSCs
on preserving vascular endothelial integrity was also reported in
in vivomodel of lung hemorrhagic shock (Pati et al., 2011).
In addition, several studies reported the efficacy of MSC
treatment in improving the survival of animals with viral
infection. Chan et al. (2016) reported how MSC injection
strongly improved the dysregulated alveolar fluid clearance
induced by the avian virus H5N1. Furthermore, the authors
reported how the treatment with MSCs improved alveolar fluid
clearance by upregulating the expression of the sodium chloride
channel that is usually downregulated by the viral infection
(Chan et al., 2016). Importantly, substantial differences in the
beneficial effect exerted by MSCs according to the age of the
animal were observed. Indeed, MSC injection induced a general
improvement in old mice (8–12 months old) by reducing
the mortality, lung edema, the total area of lung lesion. In
parallel, researchers observed a reduction in the amount of
total infiltrating lymphocytes. These effects were not appreciable
in young mice (6–8 weeks old) (Chan et al., 2016). This
age dependent sensitivity has also been observed in COVID-
19 patients. In fact, the severity of the disease increases in
aged people while children often develop mild symptoms (Liu
K. et al., 2020). However, it still remains to be understood
whether this effect is related to reduced levels of Angiotensin-
converting enzyme 2 (ACE2) receptor expressed by children,
to the immune-senescence appreciable in elderly people, or to
other phenomena (Liu K. et al., 2020; Nikolich-Zugich et al.,
2020). Conversely, Li et al. (2016) demonstrated how MSC
treatment was effective in reducing the lung injury in young
(8 weeks old) immunocompetent mouse model of viral H9N2-
AIV infection, in parallel reducing the amount of inflammatory
cytokines present at serum level.
In a comparison paper, hUC-MSCs were more effective
than BM-MSCs in improving the overall survival of H5N1-
infected mice. hUC-MSCs were shown to release angiogenin-
1 and hepatocyte growth factors that were able to enhance
the alveolar fluid clearance, thus reducing lung edema and
inflammation (Loy et al., 2019). However, despite these results,
MSC treatment was not found to be associated with a general
reduction of the viral load (Khoury et al., 2020). The ability
of MSCs to act positively in counteracting the damage caused
by viral infection was not limited to the cell therapy per se,
but as aforementioned positive results were obtained also by
the use of the cell secretome (Krasnodembskaya et al., 2010)
as well as with the extracellular vesicles (EVs) (Börger et al.,
2020). Indeed, MSC-EVs were able not only to suppress the
viral replication in lung epithelial cells (Khatri et al., 2018),
but also to exert anti-inflammatory effects (Willis et al., 2018;
Park et al., 2019; Varkouhi et al., 2019). Conversely, in an in
vitro study, the immunomodulatory effect of hUC-MSCs was
reported to be responsible for the reduced cytotoxic activity
of a subset of T lymphocytes, Vγ 9Vδ2 T lymphocytes, against
H1N1-infected A549 cells (Liu et al., 2015). On the other hand,
it has also been reported that MSCs did not affect the viral-
specific T lymphocyte activity (Karlsson et al., 2008). Indeed,
Karlsson et al. (2008) found that MSCs co-cultured with virus
specific EBV or CMV cytotoxic T lymphocytes maintained their
cytotoxic activity. These results were also confirmed by a clinical
report highlighting how patients who received MSCs for graft vs.
host disease (GVDH) treatment still maintained the capacity to
responded to CMV viral infection (Karlsson et al., 2008).
Anti-septic Properties of MSCs
For many aspects COVID-19 pathogenesis is comparable to
sepsis. Indeed, sepsis is defined as a life-threatening organ
dysfunction caused by a overreacted host response to infection
(Singer et al., 2016). As a matter of fact, COVID-19 patients are
often hospitalized for severe pneumonia that rapidly deteriorates
to multi organ failure as a consequence of infection spread and
cytokine storm (Jose and Manuel, 2020).
The pathogenesis of both sepsis and COVID-19 are indeed
characterized by the massive infiltration of immune cells to the
target organ or tissue, increased levels of cytokines and signaling
molecules released which attract more immune cells that triggers
a feedback loop that exacerbates inflammatory response causing
the formation of tissue damage and potentially leading to multi-
organ failure and death (Singer et al., 2016; Jose and Manuel,
2020). In line with this, one study demonstrated that SARS-
CoV2 infection was reported to trigger acute kidney failure in
20% of cases analyzed (Arentz et al., 2020). Another case report
highlighted that over 30% patients with COVID-19 developed
liver injury (Bhatraju et al., 2020). In both studies the authors
report that patients undergo septic shock.
MSCs have been reported to improve survival in different
preclinical models of sepsis (Lombardo et al., 2015). They have
also been shown to reduce the deleterious effects determined by
the cytokine storm typical in sepsis model. These findings were
confirmed by the reduction of plasma inflammatory cytokines
after administration of BM-MSCs in different mouse models of
sepsis, such as intraperitoneal injection of LPS (Xu et al., 2007;
Saeedi et al., 2019) or the caecal ligation and puncture (Mei et al.,
2010; Luo et al., 2014). A study using hAMSCs also reported that
treatment ofmice with cecum-puncture-induced sepsis protected
mice against death caused by diffuse peritonitis (Parolini et al.,
2014).
These effects were also confirmed in a mouse model of
ARDS and sepsis due to Escherichia coli (E. coli)-induced
pneumonia sepsis (Horie et al., 2020). Treatment with a
subpopulation of hUC-MSCs, more specifically CD362+hUC-
MSCs, resulted in the reduction of bacterial infiltration and
injury, thus ameliorating inflammatory marker levels (Horie
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et al., 2020). Similar findings were also obtained in rat models
of ARDS or ARDS combined with severe sepsis (ARDS-SS)
syndrome obtained upon caecal-ligation and puncture. In both
models, hUC-MSC administration reduced the serum levels of
inflammatory cytokines, and slightly reduced the percentages
of inflammatory cells in ascites and kidney parenchyma thus
improving the overall survival (Lee et al., 2017). Another
study reported that the beneficial effect exerted by hUC-MSC
transplantation was due to the release of the anti-microbial
peptide LL-37 (Zhu, 2017).
The anti-microbial effect of MSCs is not limited to the
MSC per se. Indeed, beneficial results have also been obtained
after injection of the secretome derived from BM-MSC culture.
These effects were strictly related to the increased expression
of the antimicrobial peptide LL-37 by MSCs primed with E.
coli (Krasnodembskaya et al., 2010). Other bioactive molecules
released by MSCs are lipocalin-2, that has been shown to
regulate the activation of neutrophils and thus improve bacteria
clearance (Gupta et al., 2012), and beta-defensin-2. Importantly,
the injection of hUC-MSCs in a mouse model of E. coli-induced
acute lung injury improved the bacteria clearance by the release
of beta-defensin-2 upon the direct triggering of the TLR4 (Sung
et al., 2016).
The beneficial effects obtained after MSC injection to
treat sepsis have been shown to be related to their strong
immunomodulatory properties. Indeed, MSCs were able to
reduce the plasma levels of different inflammatory cytokines thus
improving the lung histology (Gonzalez-Rey et al., 2009; Shin
et al., 2013; Sepúlveda et al., 2014), as well as cardiac tissue quality
(Weil et al., 2010; Manukyan et al., 2011), in different in vivo
models of sepsis. Importantly, MSC treatment can reduce the
infiltration of inflammatory cells like neutrophils, macrophages,
and T lymphocytes to the target organs in animal model of sepsis
(Mei et al., 2010; Anderson et al., 2013; Hall et al., 2013; Zhao
et al., 2014). Moreover, reduced IL-6 and IL-1b, two relevant
inflammatory cytokines in sepsis that it have been reported to
play a relevant role in COVID-19 [as highlighted by the different
clinical trials using different monoclonal antibodies targeting IL-
6 (Tocilizumab) (De Luna et al., 2020; Toniati et al., 2020) as
well as IL-1b (Anakinra) (Huet et al., 2020)], was also observed
(Wilson et al., 2015; McIntyre et al., 2018). Also, IL-10 plays
a relevant role in modulating the immune response. Indeed,
COVID-19 patients often present high plasma concentration
of this cytokine (Chiappelli et al., 2020; Huang et al., 2020),
and MSCs have been shown to modulate the serum levels of
IL-10 by stimulating its production by immune system cells.
Indeed, it has been reported that IL-10 is not directly produced
by MSCs but is a consequence of the macrophage skewing
toward anti-inflammatory M2 macrophages; an effect that seems
to be triggered by the prostaglandin E2 (PGE2) released by
MSCs (Nemeth et al., 2009). Furthermore, this effect was also
confirmed in in vivo studies. Indeed, the intraperitoneal injection
of M2 macrophages, induced by the in vitro co-culture with
BM-MSCs, in septic mice were able to improve the overall
survival (Anderson et al., 2013). The effects were due to a
general systemic reduction of immune cell infiltration in different
organs (Anderson et al., 2013). Noteworthy, when septic mice
depleted for monocytes or neutrophils were treated with MSCs,
no beneficial effects were reported, thus highlighting the crucial
role of the interactions of MSCs on immune cells in order to exert
a therapeutic effect (Nemeth et al., 2009; Hall et al., 2013).
Overall, there are numerous experimental evidences that
support the application of PDCs in the treatment of COVID-
19. The intrinsic properties of PDCs, notorius for their
immunomodulatory properties, seem to perfectly mitigate the
etiopathological characteristics of COVID-19 (Figure 2B).
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